Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial

Benralizumab is an interleukin-5 receptor α-directed cytolytic monoclonal antibody approved in several countries for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older. In the 28-week Phase III ZONDA trial (ClinicalTrials.gov identifier: NCT02075255)...

Descripción completa

Detalles Bibliográficos
Autores principales: Menzies-Gow, Andrew, Corren, Jonathan, Bel, Elisabeth H., Maspero, Jorge, Heaney, Liam G., Gurnell, Mark, Wessman, Peter, Martin, Ubaldo J., Siddiqui, Shahid, Garcia Gil, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Study Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759576/
https://www.ncbi.nlm.nih.gov/pubmed/31579676
http://dx.doi.org/10.1183/23120541.00009-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759576/
https://www.ncbi.nlm.nih.gov/pubmed/31579676
http://dx.doi.org/10.1183/23120541.00009-2019

Ejemplares similares